• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> Method for determining the risk of developing malignant primary lymphoma of central nervous system and therapeutic composition for central nervous system malignant lymphoma

Method for determining the risk of developing malignant primary lymphoma of central nervous system and therapeutic composition for central nervous system malignant lymphoma

机译：确定中枢神经系统恶性原发性淋巴瘤发生风险的方法和中枢神经系统恶性淋巴瘤的治疗组合物

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

An object of the present invention is to provide a method for conveniently determining the risk of developing malignant central lymphoma and a composition for treating central nervous system malignant lymphoma. The present invention provides a method for determining the risk of developing a central neurological malignant lymphoma of a human subject comprising the steps of detecting a mutant of GRB2 and / or MYD88 or a nucleic acid encoding it from a sample derived from the subject, , And determining that the risk of developing primary malignant lymphoma of the central nervous system of the subject when the mutant or nucleic acid encoding it is detected is high, as well as a method for diagnosing malignancy of the central nervous system of a human subject A composition for treating lymphoma, comprising a GRB2 in the MAPK pathway and / or an inhibitor of the activity of a signaling factor downstream thereof, or rituximab, wherein the central nervous system malignant lymphoma is caused by said mutant, The above objects are solved by the composition.
机译：本发明的目的是提供一种方便地确定发生恶性中央淋巴瘤的风险的方法和一种用于治疗中枢神经系统恶性淋巴瘤的组合物。本发明提供了一种用于确定人类受试者发生中枢神经系统恶性淋巴瘤的风险的方法，该方法包括以下步骤：从源自该受试者的样品中检测GRB2和/或MYD88的突变体或编码其的核酸，以及确定检测到突变体或编码该核酸的核酸时，罹患该对象的中枢神经系统原发性恶性淋巴瘤的风险很高，以及用于诊断人类对象的中枢神经系统恶性的方法治疗淋巴瘤，其在MAPK途径中包含GRB2和/或其下游信号传导因子或利妥昔单抗的活性抑制剂，其中中枢神经系统恶性淋巴瘤由所述突变体引起。上述目的通过组合物解决。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号